Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes.
- Schernthaner G Medical University of Vienna, Vienna, Austria. guntram@schernthaner.eu.
- Shehadeh N Institute of Diabetes, Endocrinology and Metabolism, Rambam Health Care Campus and the Bruce Rappaport Faculty of Medicine, Technion, P.O. Box 9602, 3109601, Haifa, Israel.
- Ametov AS Head of Endocrinology, Russian Medical Academy of Continuous Professional Education, Ministry of Healthcare of the Russian Federation, Moscow, Russia.
- Bazarova AV Department of Internal Medicine #3, Astana Medical University (NpJSC "AMU"), 49A Beybitshilik Street, Nur-Sultan City, Kazakhstan.
- Ebrahimi F Division of Endocrinology, Diabetes, and Metabolism, University Hospital Basel, Basel, Switzerland.
- Fasching P 5th Medical Department With Endocrinology, Rheumatology and Acute Geriatrics, Vienna Health Association Clinic Ottakring, 37 Montleartstraße, 1160, Vienna, Austria.
- Janež A Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Center Ljubljana, 7 Zaloška Cesta, 1000, Ljubljana, Slovenia.
- Kempler P Department of Internal Medicine and Oncology, Semmelweis University, 2/a Korányi Sándor Utca, Budapest, 1083, Hungary.
- Konrāde I Riga Stradins University, Riga, Latvia.
- Lalić NM Clinic for Endocrinology, Diabetes and Metabolic Diseases, Clinical Center of Serbia, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
- Mankovsky B Department of Diabetology, National Medical Academy for Postgraduate Education, Kiev, Ukraine.
- Martinka E National Institute of Endocrinology and Diabetology, Lubochna, Slovak Republic.
- Rahelić D Vuk Vrhovac University Clinic for Diabetes, Endocrinology and Metabolic Diseases, Merkur University Hospital, Zagreb, Croatia.
- Serafinceanu C Department of Diabetes, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
- Škrha J 3rd Department of Internal Medicine, 1st Faculty of Medicine, Charles University, 1 Ulice Nemocnice, 128 08, Prague 2, Czech Republic.
- Tankova T Department of Endocrinology, Medical University - Sofia, 2 Zdrave Street, Sofia, Bulgaria.
- Visockienė Ž Clinic of Internal Diseases, Family Medicine and Oncology, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.
- 2020-10-24
Published in:
- Cardiovascular diabetology. - 2020
English
The disclosure of proven cardiorenal benefits with certain antidiabetic agents was supposed to herald a new era in the management of type 2 diabetes (T2D), especially for the many patients with T2D who are at high risk for cardiovascular and renal events. However, as the evidence in favour of various sodium-glucose transporter-2 inhibitor (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA) accumulates, prescriptions of these agents continue to stagnate, even among eligible, at-risk patients. By contrast, dipeptidyl peptidase-4 inhibitors (DPP-4i) DPP-4i remain more widely used than SGLT2i and GLP-1 RA in these patients, despite a similar cost to SGLT2i and a large body of evidence showing no clear benefit on cardiorenal outcomes. We are a group of diabetologists united by a shared concern that clinical inertia is preventing these patients from receiving life-saving treatments, as well as placing them at greater risk of hospitalisation for heart failure and progression of renal disease. We propose a manifesto for change, in order to increase uptake of SGLT2i and GLP-1 RA in appropriate patients as a matter of urgency, especially those who could be readily switched from an agent without proven cardiorenal benefit. Central to our manifesto is a shift from linear treatment algorithms based on HbA1c target setting to parallel, independent considerations of atherosclerotic cardiovascular disease, heart failure and renal risks, in accordance with newly updated guidelines. Finally, we call upon all colleagues to play their part in implementing our manifesto at a local level, ensuring that patients do not pay a heavy price for continued clinical inertia in T2D.
- Language
-
- English
- Open access status
- gold
- Identifiers
-
- DOI 10.1186/s12933-020-01154-w
- PMID 33097060
- Persistent URL
- https://sonar.ch/global/documents/250596
Statistics
Document views: 12
File downloads:
- fulltext.pdf: 0